Global CAR-T Cell Therapy Treatment Market - Industry Trends and Forecast to 2028

Segmentation

Short Description Global CAR-T Cell Therapy Treatment Market, By Product (Autologous CAR-T Cells, Allogeneic CAR-T Cells), Structure (First Generation CAR-T Cells, Second Generation Car-T Cells, Third Generation CAR-T Cells, Fourth Generation CAR-T Cells), Targeted Antigens (Antigens on Solid Tumors, Antigens on Hematologic Malignancies, Others), Brand (Yescarta, Kymriah, Tecartus, Others), Therapeutic Application (Hematological Malignancies, Pancreatic Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Multiple Myeloma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Acute Lymphoblastic Leukemia, Others), End User (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospitals Pharmacy, Others), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and Rest of Middle East and Africa) Industry Trends and Forecast to 2028 Market Definition: CAR-T cell therapy or chimeric antigen receptor T cells are those T cells which are genetically engineered in order to produce an artificial T-cell receptor which can be used as an immunotherapy for the treatment of various cancers. Chimeric antigen receptors are those receptor proteins that have been engineered in the laboratories to provide the T-cells with the novel ability to target a specific protein. Market Segmentation: The CAR-T cell therapy treatment market is segmented on the basis of the product, structure, targeted antigens, brand, therapeutic application, end user and distribution channel. On the basis of product, the CAR-T cell therapy treatment market is segmented into autologous CAR-T cells and allogeneic CAR-T cells On the basis of structure, the CAR-T cell therapy treatment market is segmented into first generation CAR-T cells, second generation CAR-T cells, third generation CAR-T cells and fourth generation CAR-T cells On the basis of targeted antigens, the CAR-T cell therapy treatment market is segmented into antigens on solid tumors, antigens on hematologic malignancies and others On the basis of brand, the CAR-T cell therapy treatment market is segmented into yescarta, kymriah, tecartus and others On the basis of therapeutic application, the CAR-T cell therapy treatment market is segmented into hematological malignancies, pancreatic cancer, breast cancer, lung cancer, gastric cancer, multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, acute lymphoblastic leukemia and others On the basis of end user, the CAR-T cell therapy treatment market is segmented into hospitals, specialty clinics and others On the basis of distribution channel, the CAR-T cell therapy treatment market is segmented into hospitals pharmacy and others Market Players: The key market players for global CAR-T cell therapy treatment market are listed below: Autolus Atara Biotherapeutics, Inc. Amgen Inc. Bellicum Phamaceuticals, Inc. bluebird bio, inc., Adaptimmune Therapeutics plc Bristol-Myers Squibb Company Xyphos (a subsidiary of Astellas Pharma Inc.) Johnson & Johnson Services, Inc. BioAtla Inc. AbbVie Inc. Novartis AG Kite Pharma (a subsidiary of Gilead Sciences, Inc.) Aurora Biopharma Tmunity Therapeutics Cartherics Pty ltd CARINA BIOTECH Ziopharm Oncology, Inc. Cellectis SA Mustang Bio Sorrento Therapeutics, Inc. Cartesian Therapeutics, Inc. TC BioPharm Limited Celyad Oncology SA Tessa Therapeutics Ltd.

Methodology